Specialised Therapeutics Australia
About STA About Abraxane Licensing & Distribution About Abraxane Patient & Clinician Resources Contact Us
 

Specialised Therapeutics Australia

Specialised Therapeutics Australia (STA) was established to identify and license innovative anti-cancer therapies which may benefit Australians suffering from this disease. 

STA has licensed Abraxane® (nanoparticle albumin-bound paclitaxel), an anti-cancer drug for the treatment of metastatic breast cancer. Abraxane® is now approved in Australia for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy1

 

Learn more about the management

  

News & Events

Abraxis Bioscience and Specialised Therapeutics Australia Announce Approval to Market Abraxane for Metastatic Breast Cancer in Australia. <Click here>

 

 
Copyright © 2008 Specialised Therapeutics Australia Pty. Ltd. All rights reserved. Website designed by Ekko Design & Marketing.
The people appearing in the photos are models and are used for illustrative purposes only. Abraxane® is a registered trademark of Abraxis BioScience, LLC. Abraxane® is marketed under a license agreement between Abraxis BioScience, LLC and Specialised Therapeutics Australia.